MTLS — Materialise N.V.

Summary of Materialise (MTLS) Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: EUR 66.3 million, down 3.5% year-over-year; a slight increase of 2% from Q2 2025.
• Gross Profit Margin: 56.8%, consistent with prior quarters but slightly below 57.2% from Q3 2024.
• Adjusted EBIT: EUR 2.9 million (4.4% margin), down from EUR 4.4 million in Q3 2024.
• Net Profit: EUR 1.8 million, translating to EUR 0.03 per share.
• Cash Position: Increased to EUR 132 million, with a net cash position of EUR 67.7 million after drawing EUR 50 million from a credit facility.
• Operating Cash Flow: EUR 10.4 million, up from EUR 6.9 million in Q3 2024.

2. Strategic Updates and Business Highlights:

• Medical Segment: Achieved record revenue of EUR 33.3 million, growing over 10% year-over-year, driven by strong sales in medical software and devices.
• Cardiac Segment: Significant advancements with the acquisition of FEops, enhancing capabilities in AI-driven simulations for heart interventions.
• Software Segment: Transitioning to a cloud subscription model, with 83% of revenue being recurring, despite a 7% decline in total revenue to EUR 10.3 million.
• Manufacturing Segment: Revenue declined by 17% to EUR 22.7 million, but slight recovery noted compared to Q2 2025.
• Defense Sector: Increased engagement due to geopolitical factors, with potential growth opportunities identified.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Expected to be between EUR 265 million and EUR 280 million.
• Adjusted EBIT Guidance: Anticipated in the range of EUR 6 million to EUR 10 million.
• Management remains confident in the company's resilience and ability to capture growth opportunities as market conditions improve.

4. Bad News, Challenges, or Points of Concern:

• Overall Revenue Pressure: Continued headwinds in the Software and Manufacturing segments due to macroeconomic factors and geopolitical uncertainties.
• Manufacturing Segment Weakness: Persistent decline in revenue, particularly affected by the automotive sector and broader European industrial market conditions.
• Foreign Exchange Impact: Adverse effects from a weaker U.S. dollar impacting revenue.

5. Notable Q&A Insights:

• Market Exposure: The Medical segment remains the largest revenue contributor, with growth expected in newer markets like cardiac and respiratory.
• Defense Revenue: Currently a small percentage of total revenue, but potential for growth as capabilities in aerospace are leveraged.
• Manufacturing Profitability: Cost control measures are in place, but recovery in European and automotive markets is crucial for improved profitability.

This summary captures the essential elements of Materialise's Q3 2025 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.